Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — Investor Presentation (April 2021)
25 slides from Argent Biopharma's investor presentation, Apr 9, 2021
Slide 1: Leading The Way in Phytomedicines
Leading The Way in Phytomedicines Company Presentation
Slide 2: Corporate Overview
Corporate Overview MGC Pharmaceuticals Ltd (ASX/LSE: MXC) is a European Shareholder Breakdown based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived 9% 4% medicines to patients globally, for the immediate growing Directors/Management demand in the existing
Slide 3: Company Mission
Company Mission “To Build an Innovative, Vertically Integrated bio-pharma company providing Standardised, Affordable PhytoMedicines of the Highest Regulatory Compliance for Targeted global markets and patients” Financial Year Cumulative Phytocannabinoid Product Growth* $1,400,000 9,000 8,000 $1,200,
Slide 4: Board of Directors
Board of Directors Highly qualified team, each with over 15 years of relevant industry experience Roby Zomer Brett Mitchell Nativ Segev Dr. Stephen Parker Dr. Ross Walker Evan Hayes Managing Director, CEO & Executive Chairman & Non- Executive Director & Senior Independent Director & Independent Dire
Slide 5: Key Clinical and Operational Management
Key Clinical and Operational Management Leading experts in the medical cannabis space with unparalleled expertise Sasha Friedman Nicole Godresse Dr. Jonathan Grunfeld Prof. Uri Kramer Dr. Nadya Lisovoder Amir Polak Chief Operations Officer Global Chief Sales Officer Chief Medical Officer Head of Neu
Slide 6: Company Highlights
Company Highlights MGC Pharma is a European based, vertically integrated bio-pharma company supplying EU-GMP Phytocannabinoid derived products to patients, with increasing product sales in Australia, NZ, UK, Ireland and Brazil through special access schemes, and new key markets opening in EU and Isr
Slide 7: Company Strategy
Company Strategy Development and commercialisation of Phytocannabinoid derived products through a vertically integrated, core IP value chain delivering a “Nature to Medicine” business strategy with global distribution capability in place Extraction & Clinical Product Genetics Distribution Isolation
Slide 8: Products Research & Development
Products Research & Development MGC Pharma | Company Presentation | April 2021 8
Slide 9: Phytomedicines − Investigational Products
Phytomedicines − Investigational Products MGC’s Phytomedicines are Plant based products proceeding through clinical trails to obtain marketing authorization, which will allow doctors around the world to prescribe a product with accurate claim to treat symptoms These investigational products allow MG
Slide 10: Clinical R&D – Key Products Trials
Clinical R&D – Key Products Trials Three research areas based on medical experience and large data collections. MGC Pharma has commenced the following clinical trials for three of its key Phytomedicine products CannEpil®, CogniCann® and CimetrA™ Research Areas Key Products Neurology Phase IIb Clinic
Slide 11: CannEpil
Neurological CannEpil® Disorders CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy • Available to prescribe in Australia and UK as Epilepsy an Investigational Medicinal Product through early patient access schemes Target Market: • CannEpil® is an oral oil soluti
Slide 12: CogniCann
Neurological CogniCann® Disorders CogniCann® is MGC Pharma’s second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer’s disease patients quality of life • Available to prescribe in Australia as an Dementia Investigational Medicinal Product through Early Patient Access Scheme Ta
Slide 13: CimetrA™
Autoimmune CimetrA™ Disorders CimetrA™ is a phyto medicine based on natural ingredients from Artemisinin, Curcumin, and Boswellia serrata, has clinically proven effective in arresting the cytokine storm in COVID-19 patients • CimetrA™ uses an enhanced delivery system technology, a Target Market: pla
Slide 14: R&D – Preclinical
R&D – Preclinical Developing medicines that leverage its proprietary medical cannabis formula through clinical trials in Israel, Europe and Australia. Enable future medical product sales across the EU, Australia and other geographies, following the legal and regulatory approvals Neurological CepaCan
Slide 15: Proprietary MGC Drug Delivery Technology
Proprietary MGC Drug Delivery Technology Smart nanostructured materials for drug delivery Nano-emulsion, Nano particles & Core-shell microcapsules MGC is currently conducting research development on smart nanostructured materials to deliver drugs to the target sites with reduced dosage frequency and
Slide 16: Strategic Partnership with RMIT
Strategic Partnership with RMIT MGC Pharma and RMIT have developed the CannaHub, a digital research hub for the application of Phytocannabinoid derived medicines including the International Library of Cannabinoids (ILC) CannaHub was recently granted a EU REDI grant funding three doctoral students fo
Slide 17: Manufacturing, Distribution and Patient Access
Manufacturing, Distribution and Patient Access MGC Pharma | Company Presentation | April 2021 17
Slide 18: EU-GMP Manufacturing Facilities
EU-GMP Manufacturing Facilities SLOVENIA: EU-GMP certified facility capacity to manufacture up to 12,000 prescription products per month – 3 year GMP license granted. Focus on Investigational Medical Products MALTA: CimetrATM manufacturing facility ~5 million AUD grant EU Grant, operational October
Slide 19: Key Global Distribution Partners
Key Global Distribution Partners Extensive network in place providing access to hospitals, pharmacies and research institutions around the world Lenis is the Company’s wholesaler/exporter to all distributors globally and is also a direct distributor to key European markets. The Acquisition of Medici
Slide 20: Key Patient Access Agenda
Key Patient Access Agenda Strategic synergies providing expedited commercial growth Relationships on the ground Strategic Alliance with Australia’s leading Epilepsy Association, Epilepsy Action Australia Creates Doctor & Market awareness Leading to prescriptions via Early Patient Access Schemes Givi
Slide 21: Medicinal Cannabis Clinics (MCC) – the Next Phase of Growth in Australia
Medicinal Cannabis Clinics (MCC) – the Next Phase of Growth in Australia MGC Pharma has acquired 100% of MCC’s operating telehealth clinic − business assets, data and IP About MCC Strategic rationale Established in 2019 - a leading Australian telehealth Provides an established medicinal cannabis cli
Slide 22: Fully Integrated Model: Research ➜ Product Development ➜ Commercialise
Investment Proposition Fully Integrated Model: Research ➜ Product Development ➜ Commercialise Built on Decades of Experience Focussed Operations Strategically Located Technical team of globally recognised Core divisions: Operational bases close to key scientists and doctors • Research and Developmen
Slide 23: Disclaimer
Disclaimer IMPORTANT: You must read the following disclaimer before continuing. The following disclaimer applies to the following presentation and you are therefore advised to read this disclaimer carefully before reading, assessing or making any other use of the presentation. In accessing the prese
Slide 24: Disclaimer continued
Disclaimer continued Neither Turner Pope, MGC, nor their respective related bodies corporate, directors, officers, partners, their advisers, agents and/or employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to t
Slide 25: Contact details
https://mgcpharma.com.au/ @mgcpharamaceuticals @MGC_Pharma MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd UK PR – Tavistock Roby Zomer +61 8 6382 3390 Charles Vivian +44 20 7920 3150 CEO & Managing Director Charles.Vivian@tavistock.co.uk info@mgcpharma.com.au Australian PR/IR - Media and Capital Pa
Argent Biopharma — Investor Presentation (April 2021) on 6ix